Michael Bogart

600 total citations
48 papers, 413 citations indexed

About

Michael Bogart is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Michael Bogart has authored 48 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 27 papers in Physiology and 7 papers in Epidemiology. Recurrent topics in Michael Bogart's work include Asthma and respiratory diseases (27 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (19 papers) and Inhalation and Respiratory Drug Delivery (14 papers). Michael Bogart is often cited by papers focused on Asthma and respiratory diseases (27 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (19 papers) and Inhalation and Respiratory Drug Delivery (14 papers). Michael Bogart collaborates with scholars based in United States, Canada and United Kingdom. Michael Bogart's co-authors include Richard H. Stanford, Guillaume Germain, Mei Sheng Duh, François Laliberté, Beth Hahn, Elizabeth Packnett, Jennifer W. Wu, Jared Silver, Héctor Ortega and Jean‐Pierre Llanos and has published in prestigious journals such as SHILAP Revista de lepidopterología, CHEST Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Michael Bogart

41 papers receiving 404 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Bogart United States 11 313 278 47 41 39 48 413
Dragoș Bumbăcea Romania 8 236 0.8× 248 0.9× 19 0.4× 47 1.1× 31 0.8× 22 351
Sanjay Ramakrishnan United Kingdom 9 227 0.7× 229 0.8× 16 0.3× 21 0.5× 26 0.7× 24 379
Luis Miguel Franchi United States 7 273 0.9× 270 1.0× 74 1.6× 56 1.4× 48 1.2× 8 470
Carlos Almonacid Spain 8 217 0.7× 147 0.5× 19 0.4× 24 0.6× 30 0.8× 25 359
Tari Haahtela Finland 9 439 1.4× 495 1.8× 51 1.1× 73 1.8× 37 0.9× 10 571
Pippa Hall United Kingdom 8 288 0.9× 229 0.8× 13 0.3× 15 0.4× 13 0.3× 14 342
Mike Shields United Kingdom 6 159 0.5× 124 0.4× 54 1.1× 22 0.5× 26 0.7× 14 299
P. Mowinckel Norway 8 184 0.6× 186 0.7× 35 0.7× 23 0.6× 13 0.3× 10 286
Anders Andersson Sweden 11 114 0.4× 63 0.2× 22 0.5× 13 0.3× 49 1.3× 30 250
Sadia Hossain Australia 8 84 0.3× 52 0.2× 31 0.7× 7 0.2× 40 1.0× 24 259

Countries citing papers authored by Michael Bogart

Since Specialization
Citations

This map shows the geographic impact of Michael Bogart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Bogart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Bogart more than expected).

Fields of papers citing papers by Michael Bogart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Bogart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Bogart. The network helps show where Michael Bogart may publish in the future.

Co-authorship network of co-authors of Michael Bogart

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Bogart. A scholar is included among the top collaborators of Michael Bogart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Bogart. Michael Bogart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bogart, Michael, et al.. (2024). Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy. International Journal of COPD. Volume 19. 439–450.
3.
Bogart, Michael, Guillaume Germain, François Laliberté, Dominique Lejeune, & Mei Sheng Duh. (2023). Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States. International Journal of COPD. Volume 18. 1575–1586. 6 indexed citations
4.
Hanania, Nicola A., et al.. (2023). COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. International Journal of COPD. Volume 18. 407–418. 7 indexed citations
5.
Bogart, Michael, Guillaume Germain, François Laliberté, et al.. (2023). Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US. Journal of Asthma and Allergy. Volume 16. 1309–1322. 5 indexed citations
6.
Sethi, Sanjay, et al.. (2022). Impact of Mepolizumab on Exacerbations in the US Medicare Population. The Journal of Allergy and Clinical Immunology In Practice. 11(2). 546–554.e2. 2 indexed citations
7.
Mannino, David M., Michael Bogart, Guillaume Germain, et al.. (2022). Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study. Respiratory Medicine. 197. 106807–106807. 36 indexed citations
8.
Mannino, David M., et al.. (2022). Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease. Pulmonary Therapy. 8(2). 195–208. 2 indexed citations
9.
Soler, Xavier, James Siddall, Mark Small, Marjorie Stiegler, & Michael Bogart. (2022). The Burden of Nocturnal Symptoms in Patients with Chronic Obstructive Pulmonary Disease: Results of a Real-World Survey in the USA. Pulmonary Therapy. 8(3). 269–282. 3 indexed citations
10.
Silver, Jared, Michael Bogart, Néstor A. Molfino, et al.. (2021). Factors leading to discontinuation of biologic therapy in patients with severe asthma. Journal of Asthma. 59(9). 1839–1849. 14 indexed citations
11.
Silver, Jared, Néstor A. Molfino, Michael Bogart, et al.. (2021). Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis. Clinical Therapeutics. 43(12). 2064–2073. 6 indexed citations
12.
Casale, Thomas B., Néstor A. Molfino, Jared Silver, et al.. (2021). Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. Annals of Allergy Asthma & Immunology. 127(3). 354–362.e2. 26 indexed citations
13.
Ghaswalla, Parinaz, Philippe Thompson‐Leduc, Wendy Y. Cheng, et al.. (2021). Increased Health Care Resource Utilization and Costs Associated with Herpes Zoster Among Patients Aged ≥50 Years with Chronic Obstructive Pulmonary Disease in the United States. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 8(4). 502–516. 11 indexed citations
14.
Ghaswalla, Parinaz, Philippe Thompson‐Leduc, Wendy Y. Cheng, et al.. (2020). 24. Economic Burden of Herpes Zoster Among Individuals with Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study. Open Forum Infectious Diseases. 7(Supplement_1). S35–S36. 1 indexed citations
15.
Silver, Jared, Michael Bogart, Elizabeth Packnett, et al.. (2020). <p>Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma</p>. Journal of Asthma and Allergy. Volume 13. 689–699. 18 indexed citations
16.
Bogart, Michael, et al.. (2019). Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. SHILAP Revista de lepidopterología. 8 indexed citations
17.
Bogart, Michael, Richard H. Stanford, François Laliberté, et al.. (2019). <p>Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population</p>. International Journal of COPD. Volume 14. 343–352. 71 indexed citations
18.
Bogart, Michael, et al.. (2018). Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting. Respiratory Medicine. 145. 138–144. 21 indexed citations
19.
Maeng, Daniel, Jove Graham, Michael Bogart, Jing Hao, & Eric A. Wright. (2018). Impact of a pharmacist-led diabetes management on outcomes, utilization, and cost. ClinicoEconomics and Outcomes Research. Volume 10. 551–562. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dragoș Bumbăcea Breakdown of academic impact, for papers by Sanjay Ramakrishnan Breakdown of academic impact, for papers by Luis Miguel Franchi Breakdown of academic impact, for papers by Carlos Almonacid Breakdown of academic impact, for papers by Tari Haahtela Breakdown of academic impact, for papers by Pippa Hall Breakdown of academic impact, for papers by Mike Shields Breakdown of academic impact, for papers by P. Mowinckel Breakdown of academic impact, for papers by Anders Andersson Breakdown of academic impact, for papers by Sadia Hossain
Rankless by CCL
2026